BCYC
Bicycle Therapeutics Plc
NASDAQ · Healthcare · Biotechnology · GB
$3.72
+1.23%Year over year
Reported trailing growth
- Revenue
- +194.7%
- EBITDA
- +48.5%
- EBIT
- +45.4%
- EPS
- +43.8%
- Free cash flow
- +28.0%
- Operating cash flow
- +27.2%
Forward estimates
Based on analyst estimates
- Revenue
- -93.4%
- EBITDA
- -13.7%
- EPS
- -10.4%
Three-year CAGR
- Revenue
- +71.2%
- EBITDA
- -28.7%
- EBIT
- -18.0%
- Net income
- -29.5%
- EPS
- -8.6%
- Free cash flow
- -52.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026